Cited 132 times in
Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-08-22T07:17:27Z | - |
dc.date.available | 2023-08-22T07:17:27Z | - |
dc.date.issued | 2017-07 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196097 | - |
dc.description.abstract | Background: In order to increase eradication rates, vonoprazan, a novel potassium-competitive acid blocker, has been used in Helicobacter pylori eradication therapy. Aim: To summarise the results of the efficacy of vonoprazan-based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection. Methods: We conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords "vonoprazan," "takecab", "TAK-438," "potassium," "competitive," "potassium-competitive," "Helicobacter," and "pylori." Studies were included if they evaluated the eradication rate between the vonoprazan-based and proton pump inhibitor (PPI)-based triple therapies. Results: Ten studies and 10 644 patients were evaluated. The crude H. pylori eradication rate determined by intention-to-treat analysis was 87.9% and 72.8% in the vonoprazan-based triple therapy and PPI-based triple therapy respectively. The eradication rate of the vonoprazan-based triple therapy was superior to that of the PPI-based triple therapy (pooled risk ratio [RR] [95% confidence interval (CI)]=1.19 [1.15-1.24]) In addition, there was no significant difference in dropout rate due to adverse event between the regimens (pooled RR of the vonoprazan-based triple therapy [95% CI]=0.69 [0.23-2.03]). The incidence of any adverse events also did not differ between the regimens (pooled RR [95% CI]=1.02 [0.78-1.34]). Conclusions: The vonoprazan-based triple therapy showed superior efficacy in terms of H. pylori eradication as compared to the PPI-based triple therapy. In addition, the vonoprazan-based triple therapy showed comparable tolerability and incidence of adverse events. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Amoxicillin / therapeutic use | - |
dc.subject.MESH | Anti-Bacterial Agents / therapeutic use* | - |
dc.subject.MESH | Clarithromycin / therapeutic use | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Helicobacter Infections / drug therapy* | - |
dc.subject.MESH | Helicobacter pylori | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Proton Pump Inhibitors / therapeutic use* | - |
dc.subject.MESH | Pyrroles / therapeutic use* | - |
dc.subject.MESH | Sulfonamides / therapeutic use* | - |
dc.title | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Y S Jung | - |
dc.contributor.googleauthor | E H Kim | - |
dc.contributor.googleauthor | C H Park | - |
dc.identifier.doi | 10.1111/apt.14130 | - |
dc.relation.journalcode | J00061 | - |
dc.identifier.eissn | 1365-2036 | - |
dc.identifier.pmid | 28497487 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/apt.14130 | - |
dc.citation.volume | 46 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 106 | - |
dc.citation.endPage | 114 | - |
dc.identifier.bibliographicCitation | ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.46(2) : 106-114, 2017-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.